AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3548314 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide and hydrocortisone plus Estrace 2 mg b.i.d. sublingually for 3 days before and on the day of chemotherapy
Number of subjects: 39
Study 3548314 — intervention group
Group type: COMPARATOR
Intervention: Aminoglutethimide and hydrocortisone plus cyclic chemotherapy (control group)
Number of subjects: 39
Study 31748427 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 0
Study 31748427 — intervention group
Group type: COMPARATOR
Intervention: Topiroxostat
Number of subjects: 0
Study 29287667 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal sexual violence (SV) education delivered by trained CHC staff to all students seeking care.
Number of subjects: 2292
Study 29287667 — intervention group
Group type: COMPARATOR
Intervention: Information about drinking responsibly provided at control sites.
Number of subjects: 2292
Study 26980000 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH) at 34°C
Number of subjects: 43
Study 26980000 — intervention group
Group type: COMPARATOR
Intervention: Control at 36°C
Number of subjects: 43
Study 24423324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 40 mg/28 days
Number of subjects: 358
Study 24423324 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR 20 mg/28 days
Number of subjects: 358
Study 20877300 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 706
Study 20877300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 706
Study 17118706 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Water Immersion (CWI)
Number of subjects: 22
Study 17118706 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 22
Study 14670573 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect group
Number of subjects: 0
Study 14670573 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 14670573 — intervention group
Group type: COMPARATOR
Intervention: Right-hemisphere stroke subjects without neglect
Number of subjects: 0
Study 14670573 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual performance analyses
Number of subjects: 0
Study 14670573 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion analyses
Number of subjects: 0
Study 14670573 — intervention group
Group type: EXPERIMENTAL
Intervention: Group analyses
Number of subjects: 0
Study 14670573 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual analyses
Number of subjects: 0
Study 11339108 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrogen reduced iron plus NaFe(III)EDTA (EDTA:Fe 1:2)
Number of subjects: 20
Study 11339108 — intervention group
Group type: COMPARATOR
Intervention: hydrogen reduced iron
Number of subjects: 20
Study 11339108 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrogen reduced iron plus Na2EDTA (EDTA:Fe 1:2)
Number of subjects: 20
Study 11339108 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrogen reduced iron plus NaFe(III)EDTA (EDTA:Fe 1:3)
Number of subjects: 20
Study 11339108 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrogen reduced iron plus ascorbic acid (15 mg)
Number of subjects: 20
Study 10950469 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 0
Study 10950469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7699155 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin plus netilmicin
Number of subjects: 56
Study 7699155 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus netilmicin
Number of subjects: 56
Study 3588053 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 600 mg/kg/day
Number of subjects: 46
Study 3588053 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 900 mg/kg/day
Number of subjects: 46
Study 3588053 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (both dosages)
Number of subjects: 46
Study 3588053 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (total daily dosages)
Number of subjects: 46
Study 31609286 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital simulator
Number of subjects: 13
Study 31609286 — intervention group
Group type: COMPARATOR
Intervention: Textbook
Number of subjects: 13
Study 28497478 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg)
Number of subjects: 150
Study 28497478 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (30 mg)
Number of subjects: 150
Study 28497478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 150
Study 28497478 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dapoxetine (30 mg) with sildenafil citrate (50 mg)
Number of subjects: 150
Study 28497478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 28169811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Peripheral Intravenous Infiltration Scale (PIV Scale)
Number of subjects: 66
Study 28169811 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgment only
Number of subjects: 66
Study 24919561 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory supportive return to work program
Number of subjects: 0
Study 24919561 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 22676205 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular walking exercise program (3 times per week for 50 min for 6 months) and education program on diet control (once per week for 20 min for 4 weeks)
Number of subjects: 0
Study 22676205 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20464479 — intervention group
Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide, epirubicin and fluorouracil)
Number of subjects: 773
Study 20464479 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate and fluorouracil)
Number of subjects: 773
Study 18395395 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy in overcoming barriers to physical activity
Number of subjects: 61
Study 18395395 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy in making time for activity
Number of subjects: 61
Study 18395395 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy in sticking with physical activity
Number of subjects: 61
Study 18395395 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and competing demands
Number of subjects: 61
Study 15728210 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/d)
Number of subjects: 5091
Study 15728210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5091
Study 15540741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg)
Number of subjects: 1218
Study 15540741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study 11386498 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (up to 18 g/day)
Number of subjects: 20
Study 9155816 — intervention group
Group type: EXPERIMENTAL
Intervention: Device A (dental device designed to increase vertical dimension and protrude the mandible)
Number of subjects: 24
Study 9155816 — intervention group
Group type: COMPARATOR
Intervention: Device B (dental device designed to minimally increase vertical opening without protruding the mandible)
Number of subjects: 24
Study 9155816 — intervention group
Group type: EXPERIMENTAL
Intervention: Device A (for subjects who previously used Device B)
Number of subjects: 24
Study 7956987 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat gum (2.9 g beta-glucan)
Number of subjects: 20
Study 7956987 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 20
Study 3602212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (single dose)
Number of subjects: 13
Study 3602212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30325021 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene supplementation
Number of subjects: 128
Study 30325021 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene dietary advice
Number of subjects: 128
Study 30325021 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented SD increase in pyruvate
Number of subjects: 128
Study 27912155 — intervention group
Group type: EXPERIMENTAL
Intervention: dual-task motor-cognitive training
Number of subjects: 60
Study 27912155 — intervention group
Group type: EXPERIMENTAL
Intervention: single-task cognitive training
Number of subjects: 60
Study 27912155 — intervention group
Group type: COMPARATOR
Intervention: not applicable
Number of subjects: 60
Study 26573153 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (P6, ST36, LI4)
Number of subjects: 153
Study 26573153 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 153
Study 26573153 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 153
Study 23239139 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod, 7.5 mg BID for 28 days
Number of subjects: 168
Study 23239139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 21689371 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 7500 IU twice daily until birth or 34 weeks
Number of subjects: 32
Study 21689371 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 32
Study 21689371 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 32
Study 17949428 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 17949428 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study 16940833 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven‐valent pneumococcal conjugate vaccine
Number of subjects: 37868
Study 16940833 — intervention group
Group type: COMPARATOR
Intervention: Control radiographs
Number of subjects: 37868
Study 12661789 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in patients with cerebrovascular disease
Number of subjects: 133
Study 12661789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibronectin (FN) levels in patients with cerebrovascular disease
Number of subjects: 133
Study 12661789 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CRP and FN levels)
Number of subjects: 133
Study 10639541 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 percent inspired oxygen
Number of subjects: 500
Study 10639541 — intervention group
Group type: COMPARATOR
Intervention: 30 percent inspired oxygen
Number of subjects: 500
Study 9180362 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (delta9 tetrahydrocannabinol)
Number of subjects: 32
Study 9180362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9180362 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (lower dose)
Number of subjects: 32
Study 9180362 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (higher dose)
Number of subjects: 32
Study 9180362 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 32
Study 1584611 — intervention group
Group type: COMPARATOR
Intervention: Q = 0 lenses (conventional spherical surface)
Number of subjects: 12
Study 1584611 — intervention group
Group type: EXPERIMENTAL
Intervention: Q = -0.26 lenses (similar to the average corneal asphericity)
Number of subjects: 12
Study 1584611 — intervention group
Group type: EXPERIMENTAL
Intervention: Q = -0.51 lenses
Number of subjects: 12
Study 1584611 — intervention group
Group type: COMPARATOR
Intervention: Q = 0 lenses
Number of subjects: 12
Study 1584611 — intervention group
Group type: EXPERIMENTAL
Intervention: Q = -0.26 lenses
Number of subjects: 12
Study 3888591 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms levothyroxine
Number of subjects: 39
Study 3888591 — intervention group
Group type: COMPARATOR
Intervention: 500 micrograms iodide
Number of subjects: 39
Study 30995574 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial towel
Number of subjects: 125
Study 30995574 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water + treated towel
Number of subjects: 125
Study 30995574 — intervention group
Group type: EXPERIMENTAL
Intervention: Water only + treated towel
Number of subjects: 125
Study 30995574 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap and water + air dry
Number of subjects: 125
Study 30995574 — intervention group
Group type: COMPARATOR
Intervention: Untreated (placebo) towel
Number of subjects: 125
Study 27604532 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular group (intramuscular injection of betamethasone and US-guided intratenosynovial isotonic saline injection)
Number of subjects: 50
Study 27604532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratenosynovial group (saline intramuscularly and US-guided intratenosynovial betamethasone injection)
Number of subjects: 50
Study 27604532 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular group
Number of subjects: 50
Study 27604532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratenosynovial group
Number of subjects: 50
Study 25786903 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-fundoplication patients
Number of subjects: 28
Study 25786903 — intervention group
Group type: COMPARATOR
Intervention: GERD patients
Number of subjects: 28
Study 24565123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (5 mcg.kg(‐1).min(‐1)) and remifentanil (0.4 mcg.kg(‐1).min(‐1))
Number of subjects: 40
Study 24565123 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.4 mcg.kg(‐1).min(‐1)) and saline solution
Number of subjects: 40
Study 21885625 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting β-agonists
Number of subjects: 1200
Study 21885625 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 1200
Study 19506540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic arterial mapping
Number of subjects: 130
Study 19506540 — intervention group
Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 130
Study 19506540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic arterial mapping and arteriography
Number of subjects: 130
Study 17321595 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management/pharmacotherapy
Number of subjects: 116
Study 17321595 — intervention group
Group type: COMPARATOR
Intervention: Clinical management/placebo
Number of subjects: 116
Study 17321595 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly maintenance IPT/pharmacotherapy
Number of subjects: 116
Study 17321595 — intervention group
Group type: COMPARATOR
Intervention: Monthly maintenance IPT/placebo
Number of subjects: 116
Study 15204461 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic field treatment with calcitonin and exercise
Number of subjects: 40
Study 15204461 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with calcitonin and exercise
Number of subjects: 40
Study 11355928 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/m2 daunorubicin for 3 days in combination with standard dose Ara‐C and 6‐thioguanine for induction and consolidation, followed by prolonged monthly maintenance chemotherapy for at least 1 year.
Number of subjects: 0
Study 11355928 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-myeloablative preparative regimens for allogeneic transplantation.
Number of subjects: 0
Study 9476677 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia combined with general anaesthesia (group I)
Number of subjects: 16
Study 9476677 — intervention group
Group type: COMPARATOR
Intervention: High‐dose fentanyl anaesthesia (group II)
Number of subjects: 16
Study 7945128 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP at -15 mm Hg
Number of subjects: 10
Study 7945128 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP at -35 mm Hg
Number of subjects: 10
Study 7945128 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP at -45 mm Hg
Number of subjects: 10
Study 7945128 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP up to -25 mm Hg
Number of subjects: 10
Study 7945128 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP above -25 mm Hg
Number of subjects: 10
Study 7945128 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP up to -35 mm Hg
Number of subjects: 10
Study 7945128 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater levels of LBNP
Number of subjects: 10
Study 3147950 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil
Number of subjects: 40
Study 3147950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30721998 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy interventions; details on dosage and duration not available.
Number of subjects: 0
Study 30721998 — intervention group
Group type: EXPERIMENTAL
Intervention: Training music intervention providers; details on dosage and duration not available.
Number of subjects: 0
Study 30721998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention delivery supervision; details on dosage and duration not available.
Number of subjects: 0
Study 30721998 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of intervention protocol adherence; details on dosage and duration not available.
Number of subjects: 0
Study 28159015 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg IC43 without adjuvant
Number of subjects: 100
Study 28159015 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg IC43 with adjuvant
Number of subjects: 100
Study 28159015 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg IC43 with adjuvant
Number of subjects: 100
Study 28159015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24950745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 28
Study 24950745 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 28
Study 24950745 — intervention group
Group type: COMPARATOR
Intervention: Both nitroprusside and remifentanil
Number of subjects: 28
Study 23553752 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN therapy
Number of subjects: 803
Study 21888291 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stage educational strategy (critical reading guide resolution, creative discussion, group discussion)
Number of subjects: 57
Study 21888291 — intervention group
Group type: COMPARATOR
Intervention: Two-stage educational strategy (guide resolution and group discussion)
Number of subjects: 57
Study 19860553 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost (1 drop QD)
Number of subjects: 44
Study 19860553 — intervention group
Group type: COMPARATOR
Intervention: latanoprost/timolol (1 drop QD)
Number of subjects: 44
Study 17013468 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin and 50 mg zinc acetate
Number of subjects: 46
Study 17013468 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg melatonin and 50 mg zinc acetate in addition to metformin
Number of subjects: 46
Study 17013468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 14665794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart rating method for identifying and classifying MUS patients
Number of subjects: 206
Study 14665794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart rating method for identifying somatization and minor acute illness (MAI)
Number of subjects: 206
Study 14665794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart rating method for quantifying medical comorbidities in MUS patients
Number of subjects: 206
Study 14960215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for insomnia (comprising sleep hygiene, stimulus control, relaxation and cognitive therapy components)
Number of subjects: 209
Study 14960215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for insomnia
Number of subjects: 209
Study 14960215 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (control group)
Number of subjects: 209
Study 10467999 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acid-supplemented preterm infant formula
Number of subjects: 288
Study 10467999 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented control formula
Number of subjects: 288
Study 10467999 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 288
Study 8706196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐induction volume loading (12 ml x kg(‐1) Ringer's lactate)
Number of subjects: 36
Study 8706196 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐induction ephedrine sulphate (70 micrograms x kg(‐1) iv)
Number of subjects: 36
Study 8706196 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36
Study 2194304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (2 x 1.2 Gy/day, five days/week, total dose 74.4 to 79.2 Gy) with simultaneous Cisplatinum (20 mg/m2 day, i.v., five days in the first and fifth week of the radiotherapy)
Number of subjects: 22
Study 2194304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy with Cisplatinum
Number of subjects: 22
Study 157893 — intervention group
Group type: EXPERIMENTAL
Intervention: Vioform cream, Locacorten‐Vioform cream, Vioform‐Hydrocortisone cream (topical application of 30 mg clioquinol each)
Number of subjects: 4
Study 157893 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of clioquinol (30 mg)
Number of subjects: 4
Study 31186189 — intervention group
Group type: COMPARATOR
Intervention: Control (non-risk related video)
Number of subjects: 800
Study 31186189 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease (influenza) risk video
Number of subjects: 800
Study 31186189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (vaccine) risk video
Number of subjects: 800
Study 31186189 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific (air pollution) risk video
Number of subjects: 800
Study 27380904 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA without vasodilator
Number of subjects: 20
Study 27380904 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA with IV nitrate infusion
Number of subjects: 20